Hydroxyzine Hydrochloride 10 mg/5mL Solution, 473 mL — NDC 69452-0395-88 package photo

Hydroxyzine Hydrochloride 10 mg/5mL Solution, 473 mL

by Bionpharma Inc. · 473 mL in 1 BOTTLE (69452-395-88)
NDC 69452-0395-88
🏷️ FDA NDC (as labeled) 69452-395-88 billing pads the product segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 69452-395-88
Product NDC 69452-395
11-digit billing NDC 69452039588
NCPDP billing unit ML — per mL (volume)
RxCUI 995241
UNII 76755771U3
UPC 0369452395882
Application # ANDA219289
SPL Set ID 39f93633-000e-6c3f-e063-6394a90a5a0b
Established class (EPC) Antihistamine
Mechanism of action Histamine Receptor Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-07-17
Route ORAL
Dosage form SOLUTION
Substance HYDROXYZINE DIHYDROCHLORIDE
GPI-14 57200040101210
GCN Seq No 003725
GCN 13932
HICL code 001608
Ingredient (HICL) Hydroxyzine Hcl
HIC1 code Z
Therapeutic class — broad (HIC1) Body As A Whole
HIC2 code Z2
Therapeutic class — intermediate (HIC2) Antihistamines, Antiserotonins, Immunosuppressants
HIC3 code Z2P
Therapeutic class — specific (HIC3) Antihistamines - 1St Generation
AHFS code 04:04.00.00
AHFS class First Generation Antihistamines
FDB label name HYDROXYZINE 10 MG/5 ML SOLN
FDB brand name Hydroxyzine Hcl
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AA · RLD · RS
Why two NDCs? The FDA registers this code as 69452-395-88 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 69452-0395-88. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Antihistamine class.

Pharmacologic class Antihistamine
Drug family (ATC) Diphenylmethane derivatives
How it works Histamine Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerBionpharma Inc.
Application holderBIONPHARMA INC
FDA applicationANDA219289 (ANDA)
Labeler code69452
First marketedJul 2025
Product typeHuman Prescription Drug
Portfolio163 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name HYDROXYZINE 10 MG/5 ML SOLN Ingredient Hydroxyzine Hcl
📖 What it is MedlinePlus · NLM

Hydroxyzine is used to relieve itching caused by allergic skin reactions, to relieve anxiety and tension, and as a sedative before and after general anesthesia for surgery. Hydroxyzine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. It also works by decreasing activity in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Hydroxyzine is most often used to relieve anxiety and tension, or to control itching from allergic conditions like hives or eczema. It's also used as a calming medication before su...
  • Drowsiness is the most common side effect — it's actually how the medication works, so some sleepiness is expected, especially when you first start. For most people it gets better...
  • This is really important to go over with your pharmacist or doctor, because hydroxyzine interacts with a number of common drugs. Combining it with alcohol, opioid pain medicines, s...
  • Can I take hydroxyzine with my other medications?
📖 Read our full Hydroxyzine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

FlavorMint
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII XF417D3PSL
    Anhydrous citric acid is a sour, crystalline powder derived from citric acid with water removed. In medicines, it acts as a buffer to control pH, adds tartness to improve taste, and helps tablets disintegrate.
  • UNII OJ245FE5EU
    Sodium benzoate is a salt derived from benzoic acid, a preservative. It's added to medicines to prevent growth of bacteria, fungi, and other microorganisms that could spoil the product.
  • UNII C151H8M554
    A natural sugar derived from sugar cane or sugar beets. It's used as a sweetener, filler, and binder to improve taste, add bulk, and help hold tablet or capsule ingredients together.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.109 $51.51 / 473 ml
Medicaid paysCMS SDUD · 12 mo $0.1635 $77.34 / 473 ml
Medicare drug plans payPart D · Q2 2026 $0.1500 $70.95 / 473 ml
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Feb 2026 May 2026 Aug 2026 $0.133 $0.109
▼ Down 18% over the last 9 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Hydroxyzine Hydrochloride 10 mg/5mL 00121-1034-16 PAI 473 ml $0.109 AA Availability likely
Hydroxyzine Hydrochloride 10 mg/5mL 54838-0502-80 Lannett 473 ml $0.109 AA Availability likely
Hydroxyzine Hydrochloride 10 mg/5mL 62135-0502-47 Chartwell 473 ml $0.109 AA Availability likely
Hydroxyzine Hydrochloride 10 mg/5mL 62135-0750-47 Chartwell 473 ml $0.109 AA Availability likely
Hydroxyzine Hydrochloride 10 mg/5mLthis 69452-0395-88 Bionpharma 473 ml $0.109 AA Availability likely
Hydroxyzine Hydrochloride 10 mg/5mL 70954-0912-10 ANI 473 ml $0.109 AA Availability likely
Hydroxyzine Hydrochloride 10 mg/5mL 83745-0232-16 APOZEAL 473 ml $0.109 AA Availability likely
Hydroxyzine Hydrochloride 10 mg/5mL 17856-0507-01 ATLANTIC 72 cups AA FDA listed
Hydroxyzine Hydrochloride 50 mg/25mL 62135-0050-24 Chartwell 10 cups AA FDA listed
Hydroxyzine Hydrochloride 10 mg/5mL 63187-0494-04 Proficient 118 ml AA FDA listed
Hydroxyzine Hydrochloride 50 mg/25mL 68999-0050-24 Chartwell 10 cups AA FDA listed
Hydroxyzine Hydrochloride 10 mg/5mL 71656-0090-16 Saptalis 473 ml AA FDA listed
Hydroxyzine Hydrochloride 10 mg/5mL 81033-0031-44 Kesin 40 cups AA FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
Jul 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 69452-0395-88, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q3 2025 – Q1 2026 · 3 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
11.5K
Units reimbursed last 4 qtrs
2.7M
Gross reimbursed last 4 qtrs
$437.2K
Avg / prescription
$37.98
Avg / unit
$0.1635
Latest quarter Q1 2026
7.3KRx
Medicaid pays / mL
$0.1635
gross reimbursed
vs
NADAC / mL
$0.1089
acquisition cost
=
Spread
+$0.0546
+50% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
44% FFS 56% MCO
Fee-for-service · 5,027 Rx Managed care · 6,483 Rx
State Medicaid map
Alaska: no data reported AK Maine: 52,177 units · 3,740 per 100k residents ME Washington: 28,890 units · 370 per 100k residents WA Idaho: 17,818 units · 907 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 35,516 units · 619 per 100k residents MN Wisconsin: 46,778 units · 792 per 100k residents WI Michigan: 39,287 units · 391 per 100k residents MI New York: 221,653 units · 1,133 per 100k residents NY Vermont: 6,123 units · 946 per 100k residents VT New Hampshire: 3,585 units · 256 per 100k residents NH Oregon: 8,069 units · 191 per 100k residents OR Nevada: 14,016 units · 439 per 100k residents NV Wyoming: 4,905 units · 840 per 100k residents WY South Dakota: 10,478 units · 1,140 per 100k residents SD Iowa: 42,345 units · 1,320 per 100k residents IA Illinois: 48,638 units · 388 per 100k residents IL Indiana: 3,044 units · 44.4 per 100k residents IN Ohio: 54,560 units · 463 per 100k residents OH Pennsylvania: 102,162 units · 788 per 100k residents PA New Jersey: 18,939 units · 204 per 100k residents NJ Massachusetts: 11,253 units · 161 per 100k residents MA California: 227,276 units · 583 per 100k residents CA Utah: 6,805 units · 199 per 100k residents UT Colorado: 60,299 units · 1,026 per 100k residents CO Nebraska: 11,972 units · 605 per 100k residents NE Missouri: 37,732 units · 609 per 100k residents MO Kentucky: 108,759 units · 2,403 per 100k residents KY West Virginia: 29,293 units · 1,655 per 100k residents WV Virginia: 24,292 units · 279 per 100k residents VA Maryland: 36,907 units · 597 per 100k residents MD Connecticut: 5,528 units · 153 per 100k residents CT Rhode Island: no data reported RI Arizona: 54,385 units · 732 per 100k residents AZ New Mexico: 43,358 units · 2,051 per 100k residents NM Kansas: 7,115 units · 242 per 100k residents KS Arkansas: 122,891 units · 4,007 per 100k residents AR Tennessee: 152,798 units · 2,144 per 100k residents TN North Carolina: 167,803 units · 1,549 per 100k residents NC South Carolina: 46,491 units · 865 per 100k residents SC Delaware: no data reported DE Oklahoma: 48,791 units · 1,204 per 100k residents OK Louisiana: 74,223 units · 1,623 per 100k residents LA Mississippi: 53,663 units · 1,825 per 100k residents MS Alabama: 116,297 units · 2,277 per 100k residents AL Georgia: 118,561 units · 1,075 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 85,012 units · 279 per 100k residents TX Florida: 257,432 units · 1,139 per 100k residents FL
Units reimbursed · per 100k residents
44.44,007
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Arkansas 4,007 /100k
2 Maine 3,740 /100k
3 Kentucky 2,403 /100k
4 Alabama 2,277 /100k
5 Tennessee 2,144 /100k
6 New Mexico 2,051 /100k
7 Mississippi 1,825 /100k
8 West Virginia 1,655 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Hydroxyzine Hydrochloride (this brand).

Top reported reactions

Pruritus3,235
Nausea2,856
Fatigue2,765
Toxicity To Various Agents2,502
Pain2,334
Headache2,303
Completed Suicide2,239

Age at onset

Neonate46
Infant60
Child625
Adolescent549
Adult7,752
Elderly3,006

Reporter sex

47,411 reports
Male · 34%
Female · 66%
Unknown · 0%

Serious outcomes

Hospitalization14,636
Life-threatening2,286
Disabling1,042
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 4,734 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
69452-0395-88 You're viewing this 473 mL in 1 BOTTLE (69452-395-88) 2025-07-17 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 154 words

INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis.

Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies.

The physician should reassess periodically the usefulness of the drug for the individual patient.

⏱️ Dosage and Administration 174 words

DOSAGE AND ADMINISTRATION For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50 mg to 100 mg four times daily; children under 6 years, 50 mg daily in divided doses and children over 6 years, 50 mg to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg three times to four times daily; children under 6 years, 50 mg daily in divided doses and children over 6 years, 50 mg to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 mg to 100 mg in adults, and 0.6 mg/kg in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all medications, the dosage should be adjusted according to the patient’s response to therapy.

Contraindications 100 words

CONTRAINDICATIONS Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. Hydroxyzine is contraindicated in patients with a prolonged QT interval. Hydroxyzine, when administered to the pregnant mouse, rat and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range.

Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy. Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to it.

⚠️ Warnings 36 words

WARNINGS Keep out of the reach of children. Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

🤒 Adverse Reactions 126 words

ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature. Skin and appendages: Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP), fixed drug eruptions, pruritis, rash and urticaria in post marketing reports. Anticholinergic: Dry mouth.

Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

Cardiac System: QT prolongation, Torsade de Pointes. To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc. at 1-888-235-BION or 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🆘 Overdosage 163 words

OVERDOSAGE The most common manifestation of hydroxyzine overdosage is hypersedation. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken. If vomiting has not occurred spontaneously, it should be induced.

Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol, or metaraminol.

Do not use epinephrine as hydroxyzine counteracts its pressor action. Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes. ECG monitoring is recommended in cases of hydroxyzine overdose.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated.

There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

🧬 Clinical Pharmacology 130 words

CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally.

Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and its clinical effects are usually noted within 15 minutes to 30 minutes after oral administration.

📦 How Supplied / Storage and Handling 87 words

HOW SUPPLIED Hydroxyzine hydrochloride oral solution, USP 10 mg per 5 mL (teaspoonful) is a clear colourless, flavadew coolmint flavoured liquid, supplied in Pint (473 mL) bottles (NDC 69452-395-88). RECOMMENDED STORAGE Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. PROTECT FROM FREEZING PROTECT FROM LIGHT Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.

Distributed by: Bionpharma Inc. Princeton, NJ 08540 MADE IN INDIA Rev. 4/2025 FDA-04 948026874

📋 Description 66 words

DESCRIPTION Hydroxyzine hydrochloride, USP is designated chemically as (±)-2-[2-[4-( p -Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride. Its structural formula is as follows: C 21 H 27 ClN 2 O 2 •2HCl M.W. 447.83 g/mol Inactive ingredients for hydroxyzine hydrochloride oral solution, USP are: flavadew coolmint flavour; sodium benzoate; sucrose; and purified water.

Anhydrous citric acid is used for pH adjustment. The pH range is between 2.0 and 4.3. Molecular Structure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.